OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Wang on the Pace of Progress in MCL

June 25th 2019

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the pace of progress in mantle cell lymphoma (MCL).

Dr. Gainor on the PACIFIC-2 Trial in Stage III NSCLC

June 25th 2019

Justin F. Gainor, MD, director of Targeted Immunotherapy, Massachusetts General Hospital, assistant professor of medicine, Harvard Medical School, discusses the phase III PACIFIC-2 trial in stage III non–small cell lung cancer (NSCLC).

Dr. Lee on the Role of Darolutamide in M0CRPC

June 25th 2019

Richard (Rick) JaeBong Lee, MD, PhD, medical oncologist at Massachusetts General Hospital and assistant professor of medicine at Harvard Medical School, discusses the role of darolutamide in nonmetastatic castration-resistant prostate cancer (M0CRPC).

Dr. Hong on the Mechanism of Action of Tisotumab vedotin in Cervical Cancer

June 25th 2019

David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the mechanism of action of tisotumab vedotin (HuMax-TF-ADC) in patients with cervical cancer.

Dr. Davis on Caveats of the KEYNOTE-062 Trial Findings in Gastric/GEJ Cancer

June 25th 2019

S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses caveats of the phase III KEYNOTE-062 trial findings in gastric and gastroesophageal junction (GEJ) cancer.

Dr. Galal on Managing AEs Linked With CAR T-Cell Therapy

June 25th 2019

Ahmed Galal, MD, instructor, Department of Medicine, Duke Cancer Institute, discusses the management of adverse events (AEs) associated with CAR T-cell therapy.

Dr. Elhassadi on 10-Year Single-Center Experience With TP53 Status in MCL

June 22nd 2019

Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses a 10-year single-center experience with TP53 status in mantle cell lymphoma (MCL).

Dr. Cohn on Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer

June 22nd 2019

Allen L. Cohn, MD, medical oncologist, Rocky Mountain Cancer Centers, discusses the use of neoadjuvant chemotherapy in the treatment of patients with locally advanced pancreatic cancer.

Dr. McGregor on the Combination of Atezolizumab and Bevacizumab in RCC

June 22nd 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in renal cell carcinoma (RCC).

Dr. Anders on Abemaciclib in HR+ Breast Cancer With Brain Metastases

June 22nd 2019

Carey Anders, MD, director, Brain and Spine Metastasis Program, Duke Cancer Institute, discussed the use of abemaciclib, a selective CDK4/6 inhibitor, in patients with hormone receptor–positive, HER2-negative metastatic brain cancer with brain metastases.

Dr. Mirza on the Rationale for the AVANOVA Trial in Recurrent Ovarian Cancer

June 21st 2019

Mansoor Raza Mirza, MD, chief oncologist in the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, Denmark, discusses the rationale for the AVANOVA study in patients with platinum-sensitive recurrent ovarian cancer.

Dr. Rugo on Unmet Needs Beyond Second-Line Treatment in HER2+ Breast Cancer

June 21st 2019

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses unmet needs beyond second-line treatment in HER2+ breast cancer.

Dr. Yu on Combining Pembrolizumab and Olaparib in mCRPC

June 21st 2019

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combining pembrolizumab and olaparib in metastatic castration-resistant prostate cancer.

Dr. Acuna-Villaorduna on the Increase of Early-Onset CRC Diagnoses

June 21st 2019

Ana Acuna-Villaorduna, MD, Heme/Oncology fellow at Montefiore Medical Center/Albert Einstein College of Medicine, discusses the increase of early-onset colorectal cancer, specifically in African-American and Hispanic populations.

Dr. McCulloch on Data Supporting the Use of R-BAC in MCL

June 21st 2019

Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses data supporting the use of R-BAC (rituximab [Rituxan], cytarabine, and bendamustine) in mantle cell lymphoma (MCL).

Dr. Quinn on Novel Hormonal Therapies in Prostate Cancer

June 21st 2019

David I. Quinn, MD, MBBS, PhD, FRACP, FACP, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Department of Medicine, Keck School of Medicine, discusses the rise of novel hormonal therapies in prostate cancer.

Dr. Antonia on Investigational Immunotherapy Combinations in Stage III NSCLC

June 21st 2019

Scott J. Antonia, MD, PhD, instructor, Duke University School of Medicine, member, Duke Cancer Institute, discusses investigational immunotherapy combinations in stage III non–small cell lung cancer (NSCLC).

Dr. El-Khoueiry on the Role of Ramucirumab in Advanced HCC

June 20th 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses the role of ramucirumab in advanced hepatocellular carcinoma.

Expanding the Use of Immunoscore in Early-Stage CRC

June 20th 2019

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses ways to expand the use of Immunoscore in early-stage colorectal cancer.

Dr. Langer on the Current State of Immunotherapy in Advanced NSCLC

June 20th 2019

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the current state of immunotherapy in advanced non–small cell lung cancer.